Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Cerenome reports preclinical data suggesting REYOBIQ damages tumor DNA and activates immunity, with enhanced activity when combined with anti-PD-1.